QurAlis reposted this
QurAlis is proud to sponsor the first-ever @ALSNexus Conference hosted by The ALS Association taking place July 14-17, 2024 in Dallas. #precisionmedicine #neurodegenerativediseases #neurologicaldiseases https://bit.ly/3KFm1Rs
At QurAlis, we are neuro pioneers on a quest to cure. We work with a relentless pursuit of knowledge, a precise attention to craft, and an optimistic mindset to discover and develop effective precision medicines that have the potential to alter the trajectory of amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), and other neurodegenerative and neurological diseases. Founded by an internationally recognized team of neurodegenerative biologists from Harvard Medical School and Harvard University, QurAlis is advancing a pipeline with therapeutic candidates that target specific components of ALS and FTD pathology and defined patient populations based on both disease-causing genetic mutation(s) and clinical biomarkers.
External link for QurAlis
100 Cambridge Park Drive
5th Floor
Cambridge, MA 02140, US
QurAlis reposted this
QurAlis is proud to sponsor the first-ever @ALSNexus Conference hosted by The ALS Association taking place July 14-17, 2024 in Dallas. #precisionmedicine #neurodegenerativediseases #neurologicaldiseases https://bit.ly/3KFm1Rs
QurAlis is proud to sponsor the first-ever @ALSNexus Conference hosted by The ALS Association taking place July 14-17, 2024 in Dallas. #precisionmedicine #neurodegenerativediseases #neurologicaldiseases https://bit.ly/3KFm1Rs
QurAlis reposted this
QurAlis Presents! Sandy Hinckley, QurAlis' vp and head of discovery will be a featured speaker at the first @ALSNexus meeting being held July 15-17, 2024 in Dallas. Her session, "Prime Targets: What’s Next in #ALS Drug Development?" takes place Monday, July 15, 2024 at 11:25aET. Sandy's will discuss the #ALS drug development landscape and showcase some of the exciting biological targets and pathways currently being pursued in the lab in the hope of developing new ALS therapies. #precisionmedicine #neurodegenerativediseases #neurologicaldiseases https://bit.ly/3KIwLyp
QurAlis Presents! Sandy Hinckley, QurAlis' vp and head of discovery will be a featured speaker at the first @ALSNexus meeting being held July 15-17, 2024 in Dallas. Her session, "Prime Targets: What’s Next in #ALS Drug Development?" takes place Monday, July 15, 2024 at 11:25aET. Sandy's will discuss the #ALS drug development landscape and showcase some of the exciting biological targets and pathways currently being pursued in the lab in the hope of developing new ALS therapies. #precisionmedicine #neurodegenerativediseases #neurologicaldiseases https://bit.ly/3KIwLyp
QurAlis reposted this
QurAlis wishes all a happy and safe #july4th holiday as we celebrate our nation’s birthday. Happy #independenceday!
QurAlis wishes all a happy and safe #july4th holiday as we celebrate our nation’s birthday. Happy #independenceday!
QurAlis reposted this
Thrilled to have QurAlis' CEO and co-founder Kasper Roet profiled in honor of the 20th Anniversary of the The ALS Association Milton Safenowitz Post-doctoral Fellowship Program. Read about how the award impacted Kasper's research and career here https://bit.ly/45MZfkh #precisionmedicine #neurodegenerativediseases #neurologicaldiseases
QurAlis reposted this
QurAlis Presents! Sandy Hinckley, QurAlis' vp and head of discovery will be a featured speaker at the 4th Oligonucleotides for CNS Summit being held next week, July 9-11, 2024 in Boston. Sandy's presentation, "Reducing the Burden of In Vitro and In Vivo Studies for IND Submission by Streamlining Oligonucleotide Development to the Clinic," will include a discussion about identifying mis-splicing targets with QurAlis' proprietary #FlexASO technology to recover loss of #TDP-43 in ALS. Sandy's talk takes place on Thursday, July 11 at 1pET. #precisionmedicine #neurodegenerativediseases #neurologicaldiseases https://bit.ly/3VLYSCa
QurAlis Presents! Sandy Hinckley, QurAlis' vp and head of discovery will be a featured speaker at the 4th Oligonucleotides for CNS Summit being held next week, July 9-11, 2024 in Boston. Sandy's presentation, "Reducing the Burden of In Vitro and In Vivo Studies for IND Submission by Streamlining Oligonucleotide Development to the Clinic," will include a discussion about identifying mis-splicing targets with QurAlis' proprietary #FlexASO technology to recover loss of #TDP-43 in ALS. Sandy's talk takes place on Thursday, July 11 at 1pET. #precisionmedicine #neurodegenerativediseases #neurologicaldiseases https://bit.ly/3VLYSCa
QurAlis reposted this
This June, as we observe Alzheimer's and Brain Awareness Month, we spotlight the groundbreaking work of 2022 Termeer Fellow, Kasper Roet, CEO of QurAlis. Under Kasper's visionary leadership, QurAlis has recently partnered with Eli Lilly and Company to advance QRL-204, a novel therapy aimed at tackling ALS and FTD by targeting UNC13A—a key player in up to 63% of all ALS cases. This collaboration merges QurAlis' innovative FlexASO™ technology with Lilly's robust development capabilities, paving the way for potentially transformative treatments in neurodegenerative disease management. Congratulations to Kasper and his team! #leadership #STEM #TermeerFoundation #HealthcareInnovation #RareDisease #Biotech #PatientCare #biotechnology #lifescience #peopleempoweringcures #connectionsempoweringcures #leadershipmatters #healthcare #mentorship #science #mentor #leader #ceo #lifescience #bio #TermeerFellows #womeninbiotech #womenshealth #brainawarenessmonth #alzheimersandbrainawareness